<DOC>
	<DOCNO>NCT00544986</DOCNO>
	<brief_summary>The overall objective clinical study assess tolerability clinical efficacy anastrozole post-menopausal woman hormone sensitive advance breast cancer India .</brief_summary>
	<brief_title>A Prospective , Open-label Study Anastrozole Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>1 . Patients must adult ( age â‰¥ 18 year age ) postmenopausal* woman 2 . Patients must diagnose advanced breast cancer ( histologically cytological confirmation require ) i.e . TNM stage III IV disease ( locally advance metastatic breast cancer ) locoregional recurrent disease , suitable treatment local surgery radiation therapy 3 . Measurable evaluable disease 4 . Patients ER/PR positive tumour ER/PR unknown status 5 . Patients must suitable endocrine treatment anastrozole 6 . Prior adjuvant chemotherapy endocrine therapy early breast cancer allow , provide treatment complete least twelve month prior study enrollment 7 . Performance status 02 ( As per WHO Classification ) 8 . Concurrent use bisphosphonates permit . 9 . Patients must give write informed consent participation study 1 . Patients tumor know estrogen progesterone receptornegative . 2 . Estrogen hormone replacement therapy , concurrently within 6 week randomization 3 . Extensive visceral involvement ( significant hepatic involvement , brain metastasis pulmonary involvement &gt; 50 % lung ) ; serum liver enzyme SGOT SGPT great five time upper limit reference range 4 . Patients receive bone marrow transplantation randomization 5 . Any concurrent medical illness ( uncontrolled cardiac disease diabetes mellitus ) laboratory abnormality would compromise safety prevent interpretation result 6 . An estimated survival le 3 month start Study drug treatment base clinical judgment . 7 . Any systemic investigational drug within thirty day enrollment study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>post menopausal woman</keyword>
	<keyword>Post menopausal woman hormone sensitive advanced breast cancer</keyword>
</DOC>